@article {Wilde001049, author = {Jim M Wild and Joanna C Porter and Philip L Molyneaux and Peter M George and Iain Stewart and Richard James Allen and Raminder Aul and John Kenneth Baillie and Shaney L Barratt and Paul Beirne and Stephen M Bianchi and John F Blaikley and Jonathan Brooke and Nazia Chaudhuri and Guilhem Collier and Emma K Denneny and Annemarie Docherty and Laura Fabbri and Michael A Gibbons and Fergus V Gleeson and Bibek Gooptu and Ian P Hall and Neil A Hanley and Melissa Heightman and Toby E Hillman and Simon R Johnson and Mark G Jones and Fasihul Khan and Rod Lawson and Puja Mehta and Jane A Mitchell and Manuela Plat{\'e} and Krisnah Poinasamy and Jennifer K Quint and Pilar Rivera-Ortega and Malcolm Semple and A John Simpson and DJF Smith and Mark Spears and LIsa G Spencer and Stefan C Stanel and David R Thickett and A A Roger Thompson and Simon LF Walsh and Nicholas D Weatherley and Mark Everard Weeks and Dan G Wootton and Chris E Brightling and Rachel C Chambers and Ling-Pei Ho and Joseph Jacob and Karen Piper Hanley and Louise V Wain and R Gisli Jenkins}, title = {Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)}, volume = {8}, number = {1}, elocation-id = {e001049}, year = {2021}, doi = {10.1136/bmjresp-2021-001049}, publisher = {Archives of Disease in childhood}, abstract = {Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.}, URL = {https://bmjopenrespres.bmj.com/content/8/1/e001049}, eprint = {https://bmjopenrespres.bmj.com/content/8/1/e001049.full.pdf}, journal = {BMJ Open Respiratory Research} }